Immune checkpoint proteins as new target for cancer immunotherapy: literature review

Authors

  • Henrique Couto Teixeira Departamento de Parasitologia, Microbiologia e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Juiz de Fora
  • Lavínia da Silva Dias Departamento de Parasitologia, Microbiologia e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Juiz de Fora
  • Tauane Larissa Menão Departamento de Parasitologia, Microbiologia e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Juiz de Fora
  • Erick Esteves de Oliveira Departamento de Parasitologia, Microbiologia e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Juiz de Fora

DOI:

https://doi.org/10.34019/1982-8047.2019.v45.28820

Keywords:

Antibodies, Cancer, Immunotherapy, T-Lymphocytes, Immunomodulation

Abstract

A new era in cancer treatment is emerging with the use of antibodies directed against immune checkpoint proteins, known as “checkpoint inhibitors”. A novel concept of “magic bullets”, concepted by Paul Ehrlich at the beginning of the last century, as being capable of acting directly on the destruction of tumor targets, is now represented by antibodies directed against molecules which block the antitumor activity of the immune system, such as Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) and Programmed Cell Death Protein-1 (PD-1). These new immunotherapies have revolutionized the treatment of different cancer types. Studies on CTLA-4, PD-1, and their ligands in antigen presenting cells are discussed in this review. The importance of tumor antigen discovery and the role of the immune system in immune surveillance of tumors were highlighted. Also in the present study, aspects related to the effects of immunotherapies based on the use of anti-CTLA-4 and anti-PD-1/ PD-L1 monoclonal antibodies are described, such as the risk of stimulating responses to
normal tissues and other adverse effects, as well as the use of combination therapies which can improve the efficacy of cancer treatment.

Downloads

Download data is not yet available.

References

Organização das Nações Unidas (BR). OMS: câncer mata 8,8 milhões de pessoas anualmente no mundo [atualizado em 2017 Feb 3; citado em 2019 out 10] Disponível em: https://nacoesunidas.org/oms-cancer-mata-88-milhoes-de-pessoas-anualmente-no-mundo/

Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018; 175(2):313-26. doi: 10.1016/j.cell.2018.09.035

Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996; 271(5256):1734-6. doi: 10.1126/science.271.5256.1734

Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvment of PD-1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. PNAS. 2002; 99(19):12293-7. doi: 10.1073/pnas.192461099

Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res. 1970; 13:1-27.

Thomas L. Discussion of cellular and humoral aspects of hypersensitive states. In: Lawrence HS. Cellular and humoral aspects of the hypersensitive states. New York: Hoeber-Harper; 1959. 529-532.

Ribatti D. The concept of immune surveillance against tumors. The first theories. Oncotarget. 2016; 8(4):7175-80. doi: 10.18632/oncotarget.12739

Garcia-lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol. 2003; 195(3):346-55. doi: 10.1002/jcp.10290

Zinkernagel RM, Doherty PC. MHC-restricted cytotoxic T cells: studies on the biological role of Polymorphic maior transplantation antigens determining T-Cel restriction-specificity, function, and responsiveness. Adv Immunol. 1979; 27:51-177. doi: 10.1016/S0065-2776(08)60262-X

Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018; 8(86). doi: 10.3389/fonc.2018.00086

Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331 (6024):1565-70. doi: 10.1126/science.1203486

Coulie PG, Van den Eynde BJ, Van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014; 14(2):135-46. doi: 10.1038/nrc3670

Van der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev. 2002; 188(1):51-64. doi: 10.1034/j.1600-065x.2002.18806.x

Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med. 1995; 181(6):2109-17. doi: 10.1084/jem.181.6.2109

Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev of Immunol. 2011; 29:235-71. doi: 10.1146/annurev-immunol-031210-101324

Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018; 359(6382):1350-5. doi: 10.1126/science.aar4060

Chikuma S, Abbas AK, Bluestone JA. B7-independent inhibition of T cells by CTLA-4. J Immunol. 2005; 175(1):177-81. doi: 10.4049/jimmunol.175.1.177

Ha SJ, West EE, Araki K, Smith KA, Ahmed R. Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. Immunol Rev. 2008; 223:317-33. doi: 10.1111/j.1600-065X.2008.00638.x

Brunner-Weinzierl MC, Rudd CE. CTLA-4 and PD-1 Control of T-cell motility and migration: implications for tumor immunotherapy. Front Immunol. 2018; 9:2737. doi: 10.3389/fimmu.2018.02737

Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science. 1995; 270:985-88. doi: 10.1126/science.270.5238.985

Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, et al. Fc Effector function contributes to the activity of human anti-CTLA-4 Antibodies. Cancer Cell. 2018; 33(4):649-63. doi: 10.1016/j.ccell.2018.02.010

Taube JM, Anders RA, Young GD, Xu H, Sharma R, Mcmiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012; 4(127). doi: 10.1126/scitranslmed.3003689

Antonelli LR, Junqueira C, Vinetz JM, Golenbock DT, Ferreira MU, Gazzinelli RT. The immunology of Plasmodium vivax malaria. Immunol Rev. 2019;1-27. doi: 10.1111/imr.12816

Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol and Immunol. 2011; 350:17-37. doi: 10.1007/82_2010_116

Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, et al. A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments. Nat Med. 2018; 24(8):1178-91. doi: 10.1038/s41591-018-0085-8

Hui E. Immune checkpoint inhibitors. J Cell Biol. 2019; 218(3):740. doi: 10.1083/jcb.201810035

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. doi: 10.1056/NEJMoa1003466

Bilusic M, Madan RA, Gulley JL. Immunotherapy of prostate cancer: facts and hopes. Clin Cancer Res. 2017; 23(22):6764-70. doi: 10.1158/1078-0432.CCR-17-0019

Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, doubleblind, multicenter phase II study. J Clin Oncol. 2012; 30(17):2046-54. doi: 10.1200/JCO.2011.38.4032

Michael R, Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018; 379:341-35. doi 10.1056/NEJMoa1805131

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018; 379:2108-21. doi: 10.1056/NEJMoa1809615

Kaliks R. Avanços em oncologia para o não oncologista. Einstein. 2016; 14(2):294-9. doi: 10.1590/S1679-45082016MD3550

Postow M. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015; 76-83. doi: 10.1200/JCO.2017.77.6385

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372(21):2018-28. doi: 10.1056/NEJMoa1501824

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med. 2015; 372(26):2521-32. doi: 10.1056/NEJMoa1503093

Oliva S, Troia R, D'Agostino M, Boccadoro M, Gayet F. Promises and pitfalls in the use of PD-1/PD-L1 inhibitors in multiple myeloma. Front Immunol. 2018; 9:2749. doi: 10.3389/fimmu.2018.02749

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, et al. Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma. Clin Exp Immunol. 2019; 197(1):74-82. doi: 10.1111/cei.13283

Stower H. A blood-based biomarker for checkpoint inhibition. Nat Med. 2018; 24(12):1781.doi: 10.1038/s41591-018-0282-5

Zhao Y, Harrison YS, Song Y, Ji J, Huang J, Hui E. Antigen-presenting cell-intrinsic PD-1 neutralizes PD-L1 in cis to attenuate PD-1 signaling in T cells. Cell Rep. 2018; 24(2):379-90. doi: 10.1016/j.celrep.2018.06.054

Selinger B. The role of the lymphocyte functional crosstalk and regulation in the context of checkpoint inhibitor treatment-review. Front Immunol. 2019; 10:2043. doi: 10.3389/fimmu.2019.02043

Stojanovic A, Cerwenka A. Checkpoint inhibition: NK cells enter the scene. Nat Immunol. 2018; 19(7):650-2. doi: 10.1038/s41590-018-0142-y

Haanen JB, Cerundolo V. NKG2A, a new kid on the immune checkpoint block. Cell. 2018; 175(7):1720-2. doi: 10.1016/j.cell.2018.11.048

Downloads

Published

2019-11-28

How to Cite

1.
Teixeira HC, da Silva Dias L, Menão TL, Esteves de Oliveira E. Immune checkpoint proteins as new target for cancer immunotherapy: literature review. HU Rev [Internet]. 2019Nov.28 [cited 2024Jul.17];45(3):325-33. Available from: https://periodicos.ufjf.br/index.php/hurevista/article/view/28820

Issue

Vol. 45 No. 3 (2019): HU Revista 45 anos - Edição Comemorativa

Section

Artigos de Revisão da Literatura

License

Cessão de Primeira Publicação à HU Revista

Os autores mantém todos os direitos autorais sobre a publicação, sem restrições, e concedem à HU Revista o direito de primeira publicação, com o trabalho licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento irrestrito do trabalho, com reconhecimento da autoria e crédito pela citação de publicação inicial nesta revista, referenciando inclusive seu DOI.

 

 

Most read articles by the same author(s)